The Effectiveness of SGLT2 Inhibitors in CKD Patients

  • Hema Boddula Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760 https://orcid.org/0000-0001-7700-442X
  • R. Shivani Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760 https://orcid.org/0000-0002-1930-1159
  • Nayak S P Srinivas Assistant Professor, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760. https://orcid.org/0000-0003-1729-7587
  • Jitendra Vaghasia Principal, Parul College of Pharmacy and Research. Parul University, Ahamadabad, Gujarat. India, 380058
  • G. S. Chakraborthy Principal, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat. India, 391760. https://orcid.org/0000-0003-0637-0486
  • Snigdha Das Mandal Head of Dept., Pharmacology, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat. India, 391760. https://orcid.org/0000-0001-7437-6535
  • Prajwal Ghatol Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760 https://orcid.org/0000-0002-7003-2193

Abstract

Sodium-glucose cotransporter-2 inhibitors, often known as SGLT2Is, are a class of medications used largely for anti-diabetic activity in oral dose form that lowers blood glucose levels. In recent years, numerous trials have documented the use of medications for conditions including renal and cardiovascular illness that go beyond only decreasing blood sugar. Other benefits of SGLT2Is' glucose-lowering activities include slowing or halting the progression of chronic kidney disease, lowering estimated glomerular filtration rate, lowering albuminuria, improving renal and cardiovascular health, and reducing estimated glomerular filtration rate. Published clinical trials reported all of these SGLT2I effects. The studies that we reviewed for this article are the Canagliflozin CardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA - CKD) trial, Effects of SGLT2I dapagliflozin on Proteinuria in Non-Diabetic Patients with The clinical studies, SGPLT2I class of medications, and their impact on cardiovascular and renal illnesses in diabetic and non-diabetic individuals are adequately covered in this review study.


Keywords: SGLT2Is, Chronic kidney disease, dapagliflozin, Canagliflozin

Keywords: SGLT2Is, Chronic kidney disease, dapagliflozin, Canagliflozin

Downloads

Download data is not yet available.

Author Biographies

Hema Boddula, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760

Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760

R. Shivani, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760

Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760

Nayak S P Srinivas, Assistant Professor, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760.

Assistant Professor, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760.

Jitendra Vaghasia, Principal, Parul College of Pharmacy and Research. Parul University, Ahamadabad, Gujarat. India, 380058

Principal, Parul College of Pharmacy and Research. Parul University, Ahamadabad, Gujarat. India, 380058

G. S. Chakraborthy, Principal, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat. India, 391760.

Principal, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat. India, 391760.

Snigdha Das Mandal, Head of Dept., Pharmacology, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat. India, 391760.

Head of Dept., Pharmacology, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat. India, 391760.

Prajwal Ghatol, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760

Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760

References

1. Subhashini, P., Sangamithra, K. R., Naik, K. T., & Nayak, S. S. Therapeutic Approaches of Hyperkalemia Induced By Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Scientific Research Journal of Clinical and Medical Sciences, 2021; 1(3).
2. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep. 2022 May 5; 7(7):1463-1476. PMID: 35812300; PMCID: PMC9263228. https://doi.org/10.1016/j.ekir.2022.04.094
3. Kanduri SR, Kovvuru K, Hansrivijit P, Thongprayoon C, Vallabhajosyula S, Pivovarova AI, Chewcharat A, Garla V, Medaura J, Cheungpasitporn W. SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease. J Clin Med. 2020 Aug 24; 9(9):2723. PMID: 32846935; PMCID: PMC7564486.https://doi.org/10.3390/jcm9092723
4. Pecoits-Filho R, Perkovic V. Are SGLT2 Inhibitors Ready for Prime Time for CKD? Clin J Am SocNephrol. 2018 Feb 7; 13(2):318-320.. Epub 2017 Sep 11. PMID: 28893920; PMCID: PMC5967433. https://doi.org/10.2215/CJN.07680717
5. Raj s baldha, Nayak et al different metabolic pathways in diabetic kidney disease and recent advances in slowing disease progression ejpmr, 2021; 8(11):269-276
6. Zoungas S, de Boer IH. SGLT2 Inhibitors in Diabetic Kidney Disease. Clin J Am SocNephrol. 2021 Apr 7; 16(4):631-633. Epub 2021 Feb 3. PMID: 33536241; PMCID: PMC8092054. https://doi.org/10.2215/CJN.18881220
7. Mariya, A. R., Batool, A. M., Sumayya, S. P. P., Koneru, A., & Nayak, S. S. Prevalence and Evaluation of Complications in Valvular Heart Disease Patients In Tertiary Care Hospital. Asian Journal of Pharmaceutical Research and Development, 2022; 10(6):30-37. https://doi.org/10.22270/ajprd.v10i6.1187
8. Khunti, K. SGLT2 inhibitors in people with and without T2DM. Nat Rev Endocrinol 2021; 17:75-76 https://doi.org/10.1038/s41574-020-00453-2
9. Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, Ortiz A. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020 Oct 9; 13(5):728-733. PMID: 33123352; PMCID: PMC7577767. https://doi.org/10.1093/ckj/sfaa198
10. Thomson SC, Vallon V. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors. Am J Cardiol. 2019 Dec 15; 124Suppl 1(Suppl 1):S28-S35. PMID: 31741437; PMCID: PMC7258222. https://doi.org/10.1016/j.amjcard.2019.10.027
11. Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020 Jul; 8(7):582-593. Erratum in: Lancet Diabetes Endocrinol. 2020 Jun 25;: PMID: 32559474. https://doi.org/10.1016/S2213-8587(20)30162-5
12. Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes ObesMetab. 2018 Aug; 20(8):1988-1993. Epub 2018 Apr 23. PMID: 29573529; PMCID: PMC6055757. https://doi.org/10.1111/dom.13301
13. Takashima H, Yoshida Y, Nagura C, Furukawa T, Tei R, Maruyama T, Maruyama N, Abe M. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. DiabVasc Dis Res. 2018; 15(5):469-472. Epub 2018 Jun 20. PMID: 29923427. https://doi.org/10.1177/1479164118782872
14. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC; DAPA-CKD Investigators. Rationale and protocol of the DapagliflozinAnd Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020 Feb 1; 35(2):274-282. PMCID: PMC7005525. https://doi.org/10.1093/ndt/gfz290
15. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13; 46(6):462-472. Epub ahead of print. PMID: 29253846; PMCID: PMC5804835. https://doi.org/10.1159/000484633
16. Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D; CANVAS-R Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozincardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes ObesMetab. 2017 Mar; 19(3):387-393. Epub 2017 Jan 25. PMID: 28120497; PMCID: PMC5348724. https://doi.org/10.1111/dom.12829
17. Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsäßer A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2; 45(6):1445-1452. PMID: 35472672; PMCID: PMC9210861. https://doi.org/10.2337/dc21-2034
18. S P Srinivas Nayak, et al, "THE NUTRITION THERAPY IN DIABETIC PATIENTS: A REVIEW", International Journal of Research and Analytical Reviews (IJRAR), 2020; 7(3):665-676.
19. Soorya C, Balamurugan S, Ramya S, Neethirajan K, Kandeepan C, Jayakumararaj R, Physicochemical, ADMET and Druggable properties of Myricetin: A Key Flavonoid in Syzygium cumini that regulates metabolic inflammations. Journal of Drug Delivery and Therapeutics 2021; 11(4):66-73 https://doi.org/10.22270/jddt.v11i4.4890
20. Ashfaq, M., Jaffer, S., Mohammed, A. M., Sumayya, S., & Nayak, S. S. Antiplatelet and antithrombotic therapy in diabetic patients recent updates. IJAR, 2021; 7(3):76-79. Doi: https://doi.org/10.5281/zenodo.5469493
21. Patti G, Cavallari I, Andreotti F, Calabro P, Cirillo P, Denas G, et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology 2019; 16(2):113-30. https://doi.org/10.1038/s41569-018-0080-2
Crossmark
Statistics
632 Views | 23 Downloads
How to Cite
1.
Boddula H, Shivani R, S P Srinivas N, Vaghasia J, Chakraborthy GS, Mandal SD, Ghatol P. The Effectiveness of SGLT2 Inhibitors in CKD Patients. JDDT [Internet]. 15Mar.2023 [cited 25Feb.2024];13(3):141-4. Available from: https://jddtonline.info/index.php/jddt/article/view/5750